Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Связь продольных изменений уровня легких цепей нейрофиламентов в плазме с нейродегенерацией у пациентов с болезнью Альцгеймера
2019-04-22
SCID: 54.1/tfz9n6pr
Discuss with AI
ATN systemAlzheimer diseasecerebrospinal fluid biomarkersneurodegenerationplasma neurofilament light
Figures from the paper
Abstract (AI)
Importance: Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. Objective: To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD. Design, Setting, and Participants: This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018. Exposures: Clinical diagnosis, Aβ and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography), and tests on cognitive scores. Main Outcomes and Measures: The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with Aβ, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures. Results: Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had no cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low Aβ42 [P = .001], high total tau [P = .02], and high phosphorylated tau levels [P = .02]), magnetic resonance imaging measures (small hippocampal volumes [P < .001], thin regional cortices [P = .009], and large ventricular volumes [P = .002]), low fluorodeoxyglucose-positron emission tomography uptake (P = .01), and poor cognitive performance (P < .001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A-T+N+ (P < .001), A+T-N+ (P < .001), and A+T+N+ (P < .001), and increased rates of NfL levels were seen in A-T+N- (P = .009), A-T+N+ (P = .02), A+T-N+ (P = .04), and A+T+N+ (P = .002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (all P < .05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia). Conclusions and Relevance: The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.
Key Findings
1
Baseline plasma NfL concentrations increased across diagnostic groups: 32.1 ng/L in cognitively unimpaired individuals, 37.9 ng/L in mild cognitive impairment, and 45.9 ng/L in Alzheimer disease dementia.
2
Longitudinal increases in plasma NfL were associated with Alzheimer disease cerebrospinal fluid biomarkers, including low Aβ42 and high total tau.
3
Plasma NfL levels increased longitudinally across all diagnostic groups, with the greatest increase observed in participants with Alzheimer disease dementia.
4
Plasma neurofilament light (NfL) levels were higher at baseline in mild cognitive impairment and Alzheimer disease dementia than in cognitively unimpaired participants.
5
The study evaluated plasma NfL as a noninvasive longitudinal marker of neurodegeneration using up to 11 years of data from 1583 participants in the Alzheimer’s Disease Neuroimaging Initiative.
Research Object
Longitudinal plasma neurofilament light levels in individuals across the Alzheimer disease spectrum
Research Subject
Associations of plasma neurofilament light levels and their changes with Alzheimer disease diagnosis, CSF Aβ and tau biomarkers, neuroimaging measures, cognition, and ATN classification
Publication Details
Publication Date
2019-04-22
Journal
Publisher
ISSN
Cited by
723
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest